Your browser doesn't support javascript.
loading
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R; Goss, Paul E; Ingle, James N; Pritchard, Kathleen I; Celano, Paul; Muss, Hyman; Gralow, Julie; Strasser-Weippl, Kathrin; Whelan, Kate; Tu, Dongsheng; Whelan, Timothy J.
Afiliación
  • Lemieux J; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Brundage MD; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Parulekar WR; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Goss PE; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Ingle JN; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Pritchard KI; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Celano P; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Muss H; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Gralow J; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Strasser-Weippl K; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Whelan K; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Tu D; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
  • Whelan TJ; Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Cen
J Clin Oncol ; 36(6): 563-571, 2018 02 20.
Article en En | MEDLINE | ID: mdl-29328860
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama / Inhibidores de la Aromatasa / Letrozol Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: J Clin Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama / Inhibidores de la Aromatasa / Letrozol Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: J Clin Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos